H eart transplantation (HTx) is the only curative treatment for patients with advanced heart failure (HF). Identification of transplant candidates with clinical features suggesting increased morbidity and mortality while awaiting cardiac transplantation is an important issue in the management of advanced HF patients. 1, 2 In fact, these patients would benefit the most from cardiac transplantation if the surgery is performed at an appropriate time point before developing an unacceptably high risk with end-organ dysfunction that would also affect the posttransplant outcomes. Traditionally, peak oxygen consumption (peak VO 2 ) obtained during cardiopulmonary exercise testing (CPET) has been widely used to guide therapy and optimal timing of listing for HTx. [3] [4] [5] A peak VO 2 <14 mL/min per kg has been reported to be an independent predictor for 1-year mortality in ambulatory patients with advanced HF and is widely used as a cutoff for HTx listing. [3] [4] [5] [6] [7] [8] In the modern era of β-blocker and neurohormonal antagonism for medical therapy of patients with HF, a lower cutoff of 10 to 12 mL/min per kg has been suggested to better reflect the mortality risk compared with survival benefit of HTx, but was never formally tested in large patient cohorts. Furthermore, the prognosis of patients with moderately decreased peak VO 2 (10-14 mL/min per kg) has not been fully elucidated.
Furthermore, no study has compared the transplant or ventricular assist device (VAD)-free survival of patients with HF and moderately decreased peak VO 2 after CPET and the survival of patients undergoing HTx.
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In addition to the functional assessment of patients with HF, novel biomarkers of myocardial and peripheral organ function and metabolism have been reported as predictors of outcome in patients with both acute and chronic HF. medical and surgical therapies associated with unloading of the failing myocardium, and optimal medical treatment of patients with acute and chronic HF causes significant reductions in plasma BNP. 9, 12 In euvolemic patients with stable HF on optimal medical therapy, BNP levels are considered relatively stable, and dynamics in BNP likely reflect progression of cardiomyopathy. In these patients, higher levels of BNP are linked to increased risk of hospitalization for decompensated HF and death. 9, 10 Therefore, we investigated VAD-free or HTx-free survival of clinically stable outpatients with advanced HF undergoing CPET as part of an HTx evaluation in comparison with the posttransplant survival of patients who underwent HTx at our institution. We further assessed the additional impact of BNP on exercise parameters, including peak VO 2 for the assessment of overall prognosis.
Methods

Study Design
A total of 424 consecutive patients undergoing HTx evaluation at Columbia University Medical Center between 2005 and 2009 were retrospectively analyzed. Peak VO 2 was determined during maximal treadmill exercise using a metabolic cart (Medical Graphics, Minneapolis, MN) and the modified Naughton protocol. Patients were classified into 3 groups according to peak VO 2 : peak VO 2 >14 mL/min per kg, mOderately decreased peak VO 2 10 tO 14 mL/min per kg, and lOw peak VO 2 <10 mL/min per kg. Clinical characteristics, medical treatment, laboratory values, including plasma BNP, were obtained within a week from CPET. Left-ventricular ejection fraction derived from echocardiogram by biplane Simpson method, obtained within 30 days from CPET, was also collected. Previously reported prognostic markers for HF patients, such as the Heart Failure Survival Score (HFSS) 6, [13] [14] [15] and the Seattle Heart Failure Model (SHFM), 15, 16 were calculated for all patients. Survival analysis after CPET was performed with the end points defined as death, HTx, or VAD requirements. To compare the survival of outpatients with HF undergoing CPET with posttransplant survival of de novo HTx recipients, survival data of 743 patients who underwent initial HTx at our institution between 1999 and 2010 were analyzed. Patients undergoing retransplantation were excluded from the analysis. Each group of patients was further subcategorized with regard to levels of BNP. Patients were dichotomized based on the receiver operating characteristic (ROC) curve-derived cutoff value of BNP for death, HTx, or VAD requirements for all enrolled patients. The VADfree or HTx-free survival of patients in all subgroups after CPET evaluation was also compared with posttransplant survival of de novo HTx recipients at our institution. The present study was approved by the Institutional Review Board of Columbia University Medical Center.
Statistical Analysis
Data are presented as mean±SD. Normality was evaluated for each variable from normal distribution plots and histograms. For data showing a bimodal distribution, such as non-Gaussian distribution or positive or negative skewness, logarithmic transformation of the variables was performed as needed to improve normality before performing statistical analysis. Variables were compared among the groups with Student unpaired 2-tailed t test. ANOVA, with Scheffe F adjustment for multiple comparisons, was used to assess differences among the groups. Categoric variables were compared using the χ 2 test. A P value of <0.05 was considered statistically significant. VAD-free or HTx-free survival after CPET in patients undergoing transplant evaluation and posttransplant survival of patients undergoing HTx were compared using Kaplan-Meier methods with log-rank test. The cutoff value of BNP associated with death and transplant or VAD requirements was determined using an ROC curve. The association between the variables and death, HTx, or VAD requirements in patients undergoing CPET was assessed by Cox proportional hazard model. Univariable analysis was used to select potential covariates for inclusion in a multivariable analysis. Those covariates that predicted the outcome with P<0.1 were entered into the Cox multivariable analysis model. Because both HFSS and SHFM include variables, such as peak VO 2 and individual laboratory results as their covariates, these scores were not used for the multivariable analysis to avoid colinearity. The relationship between peak VO 2 or VE/VCO 2 and plasma BNP levels was analyzed with Pearson correlation coefficient. To evaluate the predictive power of a combination of peak VO 2 and plasma BNP for death, HTx, or VAD requirements, a formula which combined both peak VO 2 and BNP accompanied by their coefficients obtained from a Cox regression model (as continuous variables) was created and evaluated. Each variable was multiplied by its associated coefficient and the results were summed. All data were analyzed using the Statistical Analysis Systems software JMP 7.0 (SAS Institute Inc Cary, NC).
Results
Baseline Characteristics
Clinical characteristics of all patients at the time of CPET are summarized in Table 1 . Out of all 424 patients with HF, 167 patients showed a peak VO 2 >14 mL/min per kg, 146 patients showed a peak VO 2 10 to 14 mL/min per kg, and 111 patients had a low peak VO 2 <10 mL/min per kg. There was no difference in age, gender distribution, body mass index, and baseline heart disease among the groups. More than 80% of all patients were on β-blocker therapy and >60% of all patients were on angiotensin-converting enzyme inhibitors at the time of CPET. The medication was not significantly different among the groups; however, patients with lower peak VO 2 tended to be more frequently treated with β-blockers and neurohormonal antagonists. Blood urea nitrogen and serum creatinine concentration were higher in patients with lower peak VO 2 , and BNP values also tended to be higher in patients with lower peak VO 2 . Other laboratory variables were not significantly different among the groups. Heart rate and blood pressure at rest at the time of CPET were not significantly different among the groups. The slope of the ratio of minute ventilation to carbon dioxide production (VE/VCO 2 ) was higher in patients with peak VO 2 <10 mL/min per kg compared with those with peak VO 2 10 to 14 mL/min per kg and those with peak VO 2 >14 mL/min per kg (both P<0.01). The HFSS was lower in patients with lower peak VO 2 ; however, the SHFM was not significantly different between the groups. The mean observation period after CPET for all patients undergoing CPET was 484±381 days (range: 5-1682 days), also not significantly different between the groups.
Transplants recipients whose posttransplant survival was used for comparison with those undergoing CPET consisted of 572 male and 171 female patients, and the mean age was 53.0±12.3 years. They underwent HTx between 2005 and 2010, and the observation period for survival after HTx was 1715±1194 days (range: 0-3959 days).
VAD-Free or HTx-Free Survival of Patients With HF
The survival without transplant or VAD of patients undergoing CPET was compared with the posttransplant survival of HTx recipients ( Figure 1 ). Among patients undergoing CPET, VADfree or HTx-free survival after CPET was lower in patients with decreased peak VO 2 (1-year survival of patients with peak VO 2 >14, 14-10, and <10 mL/min per kg: 100%, 87.4%, and 71.7%, respectively; P<0.0001). When comparing the VADfree or HTx-free survival of patients with HF undergoing CPET with posttransplant survival at our institution, post-CPET, VAD-free or HTx-free survival of patients with peak VO 2 >14 mL/min per kg was better than survival after HTx (1-and 3-year survival: 100% versus 87.2% and 85.9% versus 82.2%, respectively; P=0.003). Those with a peak VO 2 10 to 14 mL/ min per kg showed VAD-free or HTx-free survival equivalent to posttransplant survival (1-and 3-year survival: 87.4% versus 87.2% and 67.2% versus 82.2%, respectively; P=0.32). Patients with peak VO 2 <10 mL/min per kg showed survival lower than post-HTx (1-and 3-year survival: 71.7% versus 87.2% and 56.1% versus 82.2%, respectively; P=0.003). We next compared the posttransplant survival of recipients who were subsequently transplanted at United Network for Organ Sharing status 1A or 1B only (n=686; 1-and 3-year survival: 85.8% and 80.8%, respectively). Patients with peak VO 2 >14 mL/min per kg showed better VAD-free or HTx-free survival (P<0.001), patients with peak VO 2 10 to 14 mL/min per kg showed equivalent VAD-free or HTx-free survival (P=0.60), and patients with peak VO 2 <10 ACE indicates angiotensin-converting enzyme; ALT, alamine aminotransferase; Ang-II, angiotensin II; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; bpm, beats per minute; BUN, blood urea nitrogen, BSA, body surface area; CPET, cardiopulmonary exercise testing; Crea, creatinine; Hb, hemoglobin; HFSS, Heart Failure Survival Score; Na, sodium; SHFM, the Seattle Heart Failure Model; T-Bili, total bilirubin; UA, uric acid; VE/VCO 2 , the slope of the ratio of minute ventilation to carbon dioxide production; VO 2 , oxygen consumption; and WBC, white blood cell count.
*The values of peak VO 2 were used to classify groups of patients by definition.
mL/min per kg showed worse VAD-free or HTx-free survival (P<0.0001) compared with posttransplant survival of United Network for Organ Sharing 1A/1B recipients. Factors associated with death, HTx, or VAD requirements in patients undergoing CPET are summarized in Table 2 . Univariable analysis revealed that low left ventricular (LV) ejection fraction, low lymphocyte subset, low sodium, high BNP levels, and low peak VO 2 were associated with death, HTx, or VAD requirements. These values were subsequently included into a multivariable analysis. In the multivariable analysis, BNP and peak VO 2 were found to be independently associated with death, HTx, or VAD requirements. ROC curve analysis identified the optimal cutoff value of BNP for death, HTx, or VAD requirements in all patients undergoing CPET as 506 pg/mL providing an area under the curve (AUC) of 0.66 (P<0.0001). This value was associated with a sensitivity and specificity of 49.2% and 76.8% for the prediction of death, HTx, or VAD, respectively (Figure 2A) .
The optimal cutoff value of peak VO 2 was identified as 11.3 mL/min per kg, providing an AUC of 0.75 (P<0.0001). This value was associated with a sensitivity and specificity of 72.3% and 67.3% for the prediction of death, HTx, orVAD, respectively ( Figure 2B ). When we performed a separate analysis for the cutoff value of peak VO 2 in patients who were treated with β-blockers and those without β-blocker therapy, the optimal cutoff value of peak VO 2 in patients on β-blockers was identified as 12.5 mL/min per kg with an AUC of 0.74 (P<0.0001) associated with a sensitivity and specificity of 81.3% and 51.5% for death, HTx, or VAD, respectively. The optimal cutoff value of peak VO 2 in patients without β-blocker was 9.4 mL/min per kg with an AUC of 0.86 (P<0.0001) associated with a sensitivity and specificity of 85.7% and 87.3%, respectively. The comparison of peak VO 2 between patients treated with and without β-blockers showed no significant differences (13.1±4.8 versus 14.4±4.8 mL/min per kg; P=0. 19) .
Further, when we performed an ROC curve analysis using VE/VCO 2 to find its optimal cutoff value for the prediction of death, HTx, or VAD, the AUC of VE/VCO 2 was 0.74, and the cutoff value was 34.8 associated with a sensitivity of 71.1% and a specificity of 71.2% ( Figure 2C ). In the present study, because the AUC for peak VO 2 was higher than that of VE/ VCO 2 , we performed all subsequent analyses only using peak VO 2.
The formula of combining peak VO 2 (mL/min per kg) and BNP (pg/mL) as continuous variables for VAD-free or HTxfree survival based on a Cox model was created as follows: (0.1653849×peakVO 2 )−(0.00050667×BNP). The AUC of the combination of peak VO 2 and BNP for VAD or HTx survival was 0.78, and a cutoff value of 1.77 was associated with a sensitivity of 83.1%, a specificity of 65.0%, and a predictive accuracy of 80.1% ( Figure 2D ). The AUCs of HFSS and SHFM for VAD or HTx survival in the present cohort of patients were 0.64 and 0.59, respectively ( Figure 2E and 2F).
VAD-Free or HTx-Free Survival of Patients With HF Stratified by Peak VO 2 and BNP
Based on the cutoff value of BNP, each group of patients undergoing CPET was classified into those with BNP≥506 pg/mL and those with BNP<506 pg/mL. The 1-year survival without HTx or VAD of patients undergoing CPET whose BNP values at the time of CPET was ≥506 pg/mL and those with BNP <506 pg/mL is shown in Figure 3 . Regardless of the BNP values at the time of CPET, none of patients with peak VO 2 >14 mL/min per kg died or required transplant or VAD surgery within a year after CPET. VAD-free or HTx-free survival of patients with peak VO 2 10 to 14 mL/min per kg and BNP<506 pg/mL was equivalent to the posttransplant survival of heart transplant recipients (1-year survival: 90.8% versus 87.2%; P=0.61). Those with a peak VO 2 10 to 14 mL/min per kg and BNP≥506 pg/mL showed worse VAD-free or HTx-free survival compared with HTx recipients (1-year survival: 79.7% versus 87.2%; P=0.01). Patients with peak VO 2 <10 mL/min per kg showed worse VAD-free or HTx-free survival compared with posttransplant survival regardless of BNP values (1-year survival: 77.2% versus 87.2%, P<0.001; and 56.1% versus 87.2%, P<0.0001, respectively). Among patients with peak VO 2 <10 mL/min per kg, the prognosis was significantly better in those with BNP<506 pg/mL compared with those with BNP≥506 pg/mL (1-year survival: 77.2% versus 56.1%; P=0.01).
Correlation Between CPET Results and Plasma BNP
Calculations of Pearson correlation coefficients revealed that peak VO 2 and plasma BNP did not show any significant association in all enrolled patients as well as in each subgroup of patients (Figure 4) . The correlation analysis between VE/VCO 2 and BNP showed only a weak correlation (r=0.15; P=0.026).
Discussion
In the present study, we demonstrate that VAD-free or HTx-free survival of patients with HF and reduced exercise Figure 1 . Kaplan-Meier survival curves of patients undergoing cardiopulmonary exercise testing (CPET) and heart transplantation. The end point for patients undergoing CPET was set as death, heart transplantation (HTx), or ventricular assist device requirements. The red line indicates patients with peak oxygen consumption (VO 2 ) >14 mL/min per kg, green line indicates patients with peak VO 2 10 to 14 mL/min per kg, blue line indicates patients with peak VO 2 <10 mL/min per kg, and black line indicates heart transplant recipients. The vertical gray dot line indicates the time point of 1 year after CPET or HTx. January 2013 tolerance to peak VO 2 10 to 14 mL/min per kg is equivalent to the survival of patients after HTx. Furthermore, we show that both peak VO 2 and plasma BNP are independently associated with death, HTx, and VAD requirements in advanced HF. Patients with peak VO 2 10 to 14 mL/min per kg and BNP levels <500 pg/mL have a VAD-free or HTx-free survival equivalent to the posttransplant survival of HTx recipients, but those with BNP levels over 500 pg/mL show worse VAD-free or HTx-free survival compared with posttransplant survival. In addition, whereas VAD-free or HTx-free survival of patients with peak VO 2 <10 mL/min per kg was worse than posttransplant survival of HTx recipients irrespective of their BNP level, the use of BNP could further segregate prognosis in this subgroup of patients.
To our knowledge, this is the first study showing a comparison between transplant and VAD-free survival of patients with decreased peak VO 2 and elevated BNP with survival after HTx. Both peak VO 2 and BNP are established as markers of risk; however, the novelty of our observation is the simple and practical observation that BNP levels are particularly useful in refining the risk of adverse outcomes in patients whose peak VO 2 is 10 to 14 mL/min per kg. Of note, all study subjects analyzed in the current study were outpatients undergoing CPET for HTx evaluation in euvolemic condition on optimized medical therapy. More than 80% of patients were on β-blockers, >60% were on angiotensin-converting enzyme inhibitors, and about 40% were on aldosterone antagonists at the time of HTx evaluation, regardless of their peak VO 2 . Of note, a higher proportion of patients with very low peak VO 2 (<10 mL/min per kg) tended to be treated by these therapies in our cohort.
The recent advancement of HF therapies has significantly improved survival of patients with advanced HF. 17 The 1-year survival of patients listed for nonurgent HTx in the United States is 89.4%, which is similar to the 1-year survival after HTx. 13 These data are consistent with the HTx-free or VAD-free ACE indicates angiotensin-converting enzyme; ALT, alamine aminotransferase; Ang-II, angiotensin II; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; bpm, beats per minute; BUN, blood urea nitrogen, BSA, body surface area; CI, confidence interval; CPET, cardiopulmonary exercise testing; Crea, creatinine; Hb, hemoglobin; HR, hazard ratio; HTx, heart transplantation; Na, sodium; T-Bili, total bilirubin; UA, uric acid; VAD, ventricular assist device; VO 2 , oxygen consumption; and WBC, white blood cell count.
survival of our patients with HF as well as the survival of patients after HTx shown in the present study. Even in the era of modern medical therapy, patients with peak VO 2 <10 mL/min per kg have a strong and definite benefit from HTx, which is also confirmed by our current study. 6, [18] [19] [20] Because of survival benefits of medical therapies, a peak VO 2 in the range of 10 to 14 mL/min per kg has become a relative indication for HTx or a gray zone. 19, 20 The International Society of Heart and Lung Transplantation guidelines state that a peak VO 2 <12 mL/min per kg should be the listing criterion in patients on β-blockers, 13 but this has never been rigorously tested in a large cohort of patients with advanced HF. Previous reports suggested that the HFSS would perform a better and more consistent risk stratification to support candidacy for HTx compared with peak VO 2 alone and should, therefore, be used as complement to peak VO 2 for patients in this gray zone. 6, [13] [14] [15] 21 Several studies revealed that the HFSS could outperform peak VO 2 in risk stratification for stable advanced HF patients in the presence of an implantable cardioverter defibrillator or cardiac resynchronization therapy, 22 which is consistent between sexes. 23 The combination of HFSS and SHFM improves the predictive ability of each individual score in patients undergoing cardiac transplant evaluation. 15 In contrast, other studies reported that the SHFM yielded only modest predictive Figure 2 . Receiver operating characteristic curves for B-type natriuretic peptide (BNP) level (A), peak oxygen consumption (VO 2 ) (B), the slope of the ratio of minute ventilation to carbon dioxide production (VE/VCO 2 ) slope (C), combination of peak VO 2 and BNP (D), the Heart Failure Survival Score (HFSS; E), and the Seattle Heart Failure Model (SHFM; F) associated with death, heart transplantation (HTx), or ventricular assist device (VAD) requirements in all patients undergoing cardiopulmonary exercise testing (CPET). AUC indicates area under the curve. Figure 3 . Kaplan-Meier survival curves of patients undergoing cardiopulmonary exercise testing (CPET) and heart transplantation (HTx) up to 1 year stratified by cutoff value of B-type natriuretic peptide (BNP) level. End point for patients undergoing CPET was set as death, HTx, or ventricular assist device requirements The solid red line indicates patients with peak oxygen consumption (VO 2 )>14 mL/ min per kg and BNP<506 pg/mL; red dotted line, peak VO 2 >14 mL/min per kg and BNP≥506 pg/mL; solid green line, peak VO 2 10 to 14 mL/min per kg and BNP <506 pg/mL; green dotted line, peak VO 2 10 to 14 mL/min per kg and BNP≥506 pg/mL; solid blue line, peak VO 2 <10 mL/ min per kg and BNP<506 pg/mL; blue dotted line, peak VO 2 <10 mL/min per kg and BNP≥506 pg/mL; and the black line indicates HTx recipients.
accuracy for outcome prediction. 24 In the present study, we showed a reasonable predictive power of peak VO 2 alone with an AUC of 0.75. Although HFSS and SHFM are powerful tools to select transplant candidates, these models require several variables to calculate the score, including variables, which may vary from day to day in patients with HF, such as heart rate and blood pressure. Furthermore, both models include LV ejection fraction as a covariable, but the calculation of an exact LV ejection fraction by echocardiogram in HF patients can sometimes be challenging especially in patients with geometric abnormality or segmental asynergy. 25, 26 We believe that the risk stratification model based on only a few objective variables would clinically be useful. The measurement of BNP is a simple and easily obtainable method in the clinical setting. BNP levels can be routinely obtained at the outpatient clinic, and it has distinct prognostic power for predicting the outcome of patients with advanced HF. A previous study by Sachdeva et al 27 is consistent with our observation showing that BNP levels and peak VO 2 are the strongest predictors for both death or urgent transplantation as well as all-cause mortality by multivariable analysis. Kociol et al 28 also reported that BNP levels at the time of discharge in euvolemic and clinically stable patients predict 1-year mortality and long-term outcomes.
In the present study, we did not directly compare the predictive power between the combination of peak VO 2 with plasma BNP levels and HFSS because the HFSS includes peak VO 2 as 1 of its covariates. Plasma BNP levels can be considered an independent marker of cardiac dysfunction because we show no correlation between each individual factor in our analysis, except a very weak correlation between BNP and VE/VCO 2 . A single measurement of BNP at the time of CPET is a simple procedure and is, in fact, recommended by the guidelines of the Heart Failure Society of America for the management of every outpatient with stable HF. 20 Our findings demonstrate that patients with a peak VO 2 of 10 to 14 mL/min per kg and BNP<500 pg/mL have a survival that is equivalent to the posttransplant survival up to 1 year without transplant or VAD implantation under careful observation.
Our study includes several limitations. Because of the observational and retrospective nature of our current study, the observation period after CPET and after cardiac transplantation was not identical between the 2 groups. Also, the combined end point of VAD, HTx, or death in comparison with survival of transplant recipients can be problematic because of the subjective nature of VAD implantation and differences in transplant waiting time and access. However, the current study was designed to analyze survival of patients evaluated for cardiac transplantation without transplantation or VAD, especially those with a peak VO 2 within the grayzone of 10 to 14 mL/min per kg. Second, because of the small number of patients we did not further divide patients with peak VO 2 10 to 14 mL/min per kg at the cutoff of 12 mL/ min per kg, although the peak VO 2 of 12 mL/min per kg is the recommended cutoff value by the International Society of Heart and Lung Transplantation. 17 However, the cutoff value of peak VO 2 alone for the prediction of death, HTx, and VAD requirements in all enrolled patients undergoing CPET was 11.3 mL/min per kg. Indeed, when we performed a separate analysis to determine the best cutoff value of peak VO 2 in patients with or without β-blocker therapy by ROC analysis, the AUC was surprisingly higher in patients without β-blocker. This might, in part, be explained by the fact that some of these patients did not tolerate β-blocker therapy attributable to hypotension. Our results show that patients with lower peak VO 2 tend to be more frequently treated with β-blockers. We speculate that at the current era of HF therapeutics β-blockade is a fundamental part of drug therapies. The AUC and the associated specificity and sensitivity for patients on β-blocker therapy were reasonably sufficient at a cutoff value of 12.5 mL/min per kg. We, therefore, suggest that a peak VO 2 <12 mL/min per kg is a reasonable determinant for transplant listing in patients under fully optimized medication. However, Figure 4 . Correlations between peak oxygen consumption (VO 2 ) and plasma B-type natriuretic peptide (BNP) levels in all patients undergoing cardiopulmonary exercise testing (CPET; A), patients with peak VO 2 >14 mL/min per kg (B), patients with peak VO 2 10 to 14 mL/min per kg (C), and patients with peak VO 2 <10 mL/min per kg (D). Red circle indicates patients with peak VO 2 >14 mL/min per kg; green circle, peak VO 2 10 to 14 mL/min per kg; blue circle, peak VO 2 <10 mL/min per kg. Gray dotted lines in panel A indicates BNP level of 506 pg/mL and peak VO 2 10 and 14 mL/min per kg. None of the panels showed significant correlations between peak VO 2 and plasma BNP level.
as reported previously, categorization of continuous variables may negate some of the prognostic information contained in these variables. 29 In addition, our study focused on peak VO 2 instead of VE/VCO 2 because it has more generally been used to evaluate HTx candidacy. However, further analysis would be required to investigate the additional impact of VE/VCO 2 on previously described prognostic markers. Third, we did not perform an additional analysis of the impact of BNP on the HFSS or the SHFM. 15 Finally, we only compared VAD-free or HTx-free survival of HF patients undergoing CPET with the posttransplant survival of HTx recipients without comparing their quality of life and quality-adjusted life years after CPET or HTx. We assume that the quality of life in HTx patients is superior to that of patients with exercise intolerance in the range of peak VO 2 10 to 14 mL/min per kg, which is an additional factor to be included when considering the appropriate timing for HTx listing. Further studies are required to also evaluate the cost-effectiveness of managing HF patients awaiting HTx and the posttransplant management as well as their quality of life. Finally, the analysis is restricted to data from a single center, and the outcome reflects the management of patients with advanced HF and after HTx at our institution. There may be changes in the medical management and eligibility for transplantation during the study period. However, we believe that our study cohort was on a generally approved and modern pharmacological treatment regimen with a majority of patients on β-blockers at the time of CPET.
In conclusion, we demonstrate equivalent VAD-free or HTx-free survival of patients with HF and peak VO 2 between 10 to 14 mL/min per kg and posttransplant survival of HTx recipients. Furthermore, we show the additional impact of BNP measurements for the risk stratification of advanced HF patients with decreased exercise tolerance. These findings provide helpful guidance for the risk stratification and clinical management strategies of patients with advanced HF when considering HTx listing. These findings apply to ambulatory patients stable for CPET who are in a euvolemic state and on optimized medical therapy.
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